Clinical trials: TACE, completed
HCC - Hepatocellular Carcinoma
Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Unresectable hepatocellular carcinoma (uHCC) constitutes a significant health burden in the Asia-Pacific (APAC) region, particularly in China, where it is frequently associated with hepatitis B virus (HBV) infection and diagnosed…
- Trial name
- NCT07109336
- Testing
- Heterogeneous Treatment Effect-Based Decision Model
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Zhongda Hospital
Colorectal Cancer Metastatic
Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).
Background Hepatic metastases of colorectal cancer (MCC) is quite common and is a major source of morbidity and mortality. There has been evidence to show that hepatic arterial chemoembolisation using DC beads (drug eluting…
- Trial name
- NCT02350400
- Testing
- DEBIRI
- Where
- 2 sites in Singapore
- Volunteers
- 5 people
- Sponsor
- Singapore General Hospital
Carcinoma, Hepatocellular
Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance
Patients will be enrolled based on presence of HCC and eligibility for TACE. They will be randomized to one of two arms for imaging navigation to the optimal catheter location for chemotherapy injection to treat the first…
- Trial name
- NCT00926536
- Testing
- C-arm CT + DSA as needed, DSA only
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Stanford University
Hepatocellular Carcinoma
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma
This is a non-randomized, prospective, pilot, Multicenter Study of Drug-eluting bead transarterial chemoembolization (DEB-TACE) using Doxorubicin-Loaded Embozene® Tandem™ Microspheres to treat hepatocellular carcinoma (HCC).
- Trial name
- MIRACLE I (NCT01798134)
- Testing
- TANDEM™
- Where
- 7 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
Drug-eluting Bead in Hepatocellular Carcinoma
In unresectable hepatocellular carcinoma, TACE using Lipiodol/anti cancer agent emulsion is the standard treatment and reported as a significantly better treatment through randomized comparison study like Llovet, etc.
- Trial name
- REDEBUT (NCT01332669)
- Testing
- DebDox TACE
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
Adjuvant transarterial chemoembolization (TACE) is widely adopted in China for resectable hepatocellular carcinoma (HCC), yet its efficacy remains inconsistent.
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Adjuvant Therapy, Machine Learning
- Trial name
- HCC (NCT07562763)
- Where
- China
- Volunteers
- 1,005 people
- Sponsor
- Anhui Provincial Hospital
Carcinoma, Hepatocellular
Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE
Background Hepatic intra-arterial chemoembolization (TACE) is proposed when potentially curative therapy (eg. surgical resection, percutaneous ablation)is no longer possible.
- Trial name
- PRECISION-IT (NCT00936689)
- Testing
- Selective TACE via microsphere loaded with Doxorubicin, Selective traditional TACE
- Where
- 5 sites in Italy
- Volunteers
- 178 people
- Sponsor
- Rita Golfieri
Hepatocellular Carcinoma, Rapamycin
Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC
To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients…
- Trial name
- NCT02724332
- Testing
- Rapamycin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Recurrent Hepatocellular Carcinoma
Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion
The purpose of this study is to compare the treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion.
- Trial name
- HCCTACEAFP (NCT02728219)
- Testing
- TACE, Hepatectomy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cancer, Surgery
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
This observational clinical cohort study aims to evaluate the clinical utility of LiverMultiScan in quantifying liver health prior to liver resection or TACE.
- Conditions
- Liver Cancer, Surgery, Liver Regeneration, Colorectal Cancer Metastatic
- Trial name
- Hepatica (NCT03213314)
- Testing
- Multiparameter magnetic resonance imaging
- Where
- 2 sites in United Kingdom
- Volunteers
- 149 people
- Sponsor
- University of Edinburgh
Hepatocellular Carcinoma
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with BCLC stage hepatocellular carcinoma (HCC).
- Trial name
- NCT02856126
- Testing
- Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, TACE regimen
- Where
- 7 sites in China
- Volunteers
- 214 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Transcatheter arterial chemoembolization (TACE) had been proved to improve the survivals for middle stage hepatocellular carcinoma (HCC), but for advanced stage HCC its' efficacy had not been proved.
- Trial name
- TACEHCC (NCT00646100)
- Testing
- transcatheter arterial chemoembolization
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Predictive Model for Pain After TACE
The main aim of this study was to analyze the risk factors that helped to predict the pain after transarterial chemoembolization (TACE).This was a prospective observational study enrolled all hepatocellular carcinoma (HCC)…
- Trial name
- NCT05545046
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Yantai Yuhuangding Hospital
Hepatocellular Carcinoma
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
- Trial name
- BRISK TA (NCT00908752)
- Testing
- Brivanib, TACE Therapy
- Where
- 94 sites in United States, Argentina and 11 more
- Volunteers
- 734 people
- Sponsor
- Bristol-Myers Squibb
Liver Cancer
Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma
To evaluate local tumor control and survival rate after repeated transarterial chemoembolization(TACE) using three different protocols in hepatocellular carcinoma (HCC) patients.
- Trial name
- NCT02038296
- Testing
- transarterial chemoembolization
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Guangdong Provincial People's Hospital
Hepatocellular Carcinoma, RFS
Postoperative Adjuvant Therapy of HCC Based on PD-1
For the treatment of hepatocellular carcinoma, liver resection is still one of the optimal options, but the recurrence rate is as high as 70% five years after the operation, and the prognosis of patients with high-risk recurrence…
- Trial name
- NCT05307926
- Testing
- PD-1 inhibitors, TACE
- Where
- China
- Volunteers
- 573 people
- Sponsor
- Chen Xiaoping
Carcinoma, Hepatocellular
Safety and Efficacy of "Immuncell-LC" in TACE Therapy
To evaluate the efficacy and safety of 'Immuncell-LC group' and 'non-treatment group' in the patients undergone Transarterial Chemoembolization for intermediate stage hepatocellular carcinoma
- Trial name
- NCT02856815
- Testing
- Immuncell-LC
- Where
- 3 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- GC Cell Corporation
Hepatocellular Carcinoma Non-resectable
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and sintilimab in patients with unresectable advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599790
- Testing
- TACE combined with lenvatinib and sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Effect of Nutritional Indices on the Prognosis of HCC Patients
Primary liver cancer has recently ranked among the leading causes of cancer death, with hepatocellular carcinoma (HCC) accounting for 75%-85% of these cases.
- Trial name
- NCT05635279
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Juan Kang
Liver Cancer
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
The purpose of the study is to find out the effects of using nivolumab with Drug Eluting Bead Transarterial Chemoembolization (deb-TACE) in the treatment of liver cancer.
- Trial name
- NCT03143270
- Testing
- Drug Eluting Bead Transarterial Chemoembolization, Nivolumab
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center